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Abstract
Background: Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In
PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide signiﬁcantly reduced the risk of radiographic
progression by 81% (hazard ratio [HR], 0.19; P< .0001) and reduced the risk of death by 29% (HR, 0.71; P< .0001) compared with
placebo in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Methods: To evaluate treatment effects, safety, and pharmacokinetics of enzalutamide in East Asian patients from the PREVAIL
trial, we performed a post hoc analysis of the Japanese, Korean, and Singaporean patients. PREVAIL enrolled patients with
asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer who had progressed on
androgen deprivation therapy. During the study, patients received enzalutamide (160mg/d) or placebo (1:1) until death or
discontinuation because of radiographic progression or skeletal-related event and initiation of subsequent therapy. Centrally
assessed radiographic progression-free survival (rPFS) and overall survival (OS) were coprimary endpoints. The secondary endpoints
of the PREVAIL trial were investigator-assessed rPFS, time to initiation of chemotherapy, time to prostate-speciﬁc antigen (PSA)
progression, and PSA response (≥50% decline).Editor: Giuseppe Lucarelli.
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Results: Of 1717 patients, 148 patients were enrolled at sites in East Asia (enzalutamide 73, placebo 75). Treatment effect
Kim et al. Medicine (2017) 96:27 Medicineof enzalutamide versus placebo was consistent with that for the overall population as indicated by the HRs (95% conﬁdence interval)
of 0.38 (0.10–1.44) for centrally assessed rPFS, 0.59 (0.29–1.23) for OS, 0.33 (0.19–0.60) for time to chemotherapy, and 0.32
(0.20–0.50) for time to PSA progression. In East Asian patients, PSA responses were observed in 68.5% and 14.7% of enzalutamide-
and placebo-treated patients, respectively. The enzalutamide plasma concentration ratio (East Asian:non-Asian patients) was 1.12
(90% conﬁdence interval, 1.05–1.20) at 13 weeks. Treatment-related adverse events grade ≥3 occurred in 1.4% and 2.7% of
enzalutamide- and placebo-treated East Asian patients, respectively.
Conclusions:Treatment effects and safety of enzalutamide in East Asian patients were generally consistent with those observed in
the overall study population from PREVAIL.
ClinicalTrials.gov number: NCT01212991
Abbreviations: AE = adverse event, AR = androgen receptor, CI = conﬁdence interval, CRPC = castration-resistant prostate
cancer, ECOG = Eastern Cooperative Oncology Group, ENZA = enzalutamide, HR = hazard ratio, mCRPC =metastatic castration-
resistant prostate cancer, OS = overall survival, PSA = prostate-speciﬁc antigen, rPFS = radiographic progression-free survival, SRE
= skeletal-related event.
Keywords: antineoplastic agents, Asia, castration-resistant, disease-free survival, MDV 3100, prostatic neoplasms[20,21]1. Introduction
Prostate cancer is less common in Asian countries than inWestern
countries,[1] but incidence appears to be increasing and may
be associated with demographic aging, changes in diet, and
increased utilization of prostate-speciﬁc antigen (PSA)
screening.[1–4] Epidemiologic data across the 3 East Asian
countries (Japan, Korea, and Singapore) that contributed patients
for this analysis are similar when differences in the size of the
populations are accounted for.[1,5] Prostate cancer is the 6th-
leading cause of male cancer mortality in Japan and Singapore
and the 7th-leading cause of male cancer mortality in Korea.[2]
There are an estimated 64,900 new cases of prostate cancer[6] and
11,600 deaths from prostate cancer[7] annually in Japan. In
Korea, there are approximately 9000 new prostate cancer cases
and 1500 deaths annually,[8] and in Singapore, there are about
1200 new diagnoses of prostate cancer and about 170 deaths
from prostate cancer annually.[2] In addition, compared with
those in Western countries, patients in Asian countries often
present with more advanced disease.[1,9,10]
Androgen suppression with androgen-deprivation therapy or
castration is the primary ﬁrst-line treatment for metastatic
prostate cancer. Although most patients initially respond to
androgen-deprivation therapy, the disease will eventually
progress to castration-resistant prostate cancer (CRPC) in nearly
all patients.[11–14] Preclinical evidence has demonstrated that
overexpression of the androgen receptor (AR) is sufﬁcient to
confer resistance to androgen deprivation in prostate cancer cell
lines.[15,16] Until recently, docetaxel has been the only option
for men with metastatic castration-resistant prostate cancer
(mCRPC)[17]; however, progression is inevitable.[18] In Japan,
Korea, and Singapore, there are currently limited options for
noncytotoxic agents to treat mCRPC.[19] Thus, there is a need for
additional therapies in these regions that may have higher
proportions of patients presenting with metastatic disease.[1,9,10]
In PREVAIL, an international, phase III, randomized trial, the
AR signaling inhibitor enzalutamide (ENZA) (Medivation, Inc.,
San Francisco, CA [Medivation was acquired by Pﬁzer Inc in
September 2016]) signiﬁcantly reduced the risk of radiographic
progression by 81% (hazard ratio [HR], 0.186; P< .001),
reduced the risk of death by 29% (HR, 0.706; P< .001), and
reduced the risk of skeletal-related events (SREs) by 28% (HR,
0.720; P< .001) compared with placebo in chemotherapy-naïve2men with mCRPC. The most common adverse events (AEs)
with ENZA treatment in PREVAIL were fatigue, back pain,
constipation, and arthralgia. ENZA is now approved for use in
Japan and Korea in men with CRPC regardless of the patient’s
prior chemotherapy exposure. In Singapore, it is approved for use
in men with mCRPC postchemotherapy.
In this post hoc analysis of the PREVAIL trial, we evaluated the
treatment effects, safety, and pharmacokinetic exposure of
ENZA versus placebo in patients treated in Japan, Korea, and
Singapore.2. Methods
The fullmethodology, including patient eligibility and full endpoint
deﬁnitions, of the international, randomized, double-blind, place-
bo-controlled phase III PREVAIL trial (NCT01212991) has been
previously reported.[20] PREVAIL was approved by the indepen-
dent review board at each participating site and was conducted
according to provisions of the Declaration of Helsinki and Good
Clinical Practice Guidelines of the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use.2.1. Patients
Patients were eligible for enrollment if they had a histologically or
cytologically conﬁrmed adenocarcinoma of the prostate that was
castration resistant, had not received cytotoxic chemotherapy
or abiraterone acetate, had an Eastern Cooperative Oncology
Group (ECOG) Performance Status of 0 or 1 (no symptoms or
ambulatory but restricted in strenuous activity), and were
asymptomatic or mildly symptomatic per the Brief Pain Inventory
Short Form question 3 (i.e., pain score 0–3).[22] Patients with
conditions that could lower the seizure threshold (i.e., brain
metastases, history of seizure, concurrent medications) or those
with a history of chemotherapy were excluded.2.2. Study design
Patients were enrolled from September 2010 to September 2012
at 207 sites globally, of which 21 were in Japan, 7 in Korea, and 2
in Singapore. Enrollment occurred in Japan between November
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Figure 1. PREVAIL patient disposition (CONSORT diagram).
∗
Randomization was stratiﬁed by study site. ITT= intent-to-treat, rPFS= radiographic progression-
free survival.
Kim et al. Medicine (2017) 96:27 www.md-journal.com2011 and May 2012, in Korea between November 2011 and
September 2012, and in Singapore between October 2011
and April 2012. Patients were randomized 1:1 to receive either
160mg oral ENZA or placebo once daily (Fig. 1). Randomization
was stratiﬁed according to the study site. Treatment was
discontinued for any of the following reasons: occurrence of
unacceptable side effects, conﬁrmed radiographic progression, or
conﬁrmed SRE and the initiation of cytotoxic therapy or
investigational agent for prostate cancer.
2.3. Endpoints
The coprimary endpoints were radiographic progression-free
survival (rPFS) determined by independent central review and
overall survival (OS). A prespeciﬁed, interim analysis of rPFS
occurred on May 6, 2012, upon the occurrence of 439 rPFS
events. Secondary endpoints included rPFS by investigator
review, time to initiation of chemotherapy, time to PSA
progression, PSA response, and time to SRE. Predose plasma
concentrations of ENZA and N-desmethyl ENZA, its active
metabolite, were measured at weeks 5, 13, and 25.
Radiographic disease progression was evaluated using the
Prostate Cancer Clinical Trials Working Group[23] guidelines for
bone disease and Response Evaluation Criteria in Solid Tumors
version 1.1 for soft-tissue disease.[24] Radiographic disease3progression included conﬁrmed new bone lesions and new
soft-tissue lesions. PSA response was deﬁned as a decline in PSA
≥50% from baseline to the lowest postbaseline PSA level as
determined by the local laboratory (conﬁrmed by a second
assessment conducted ≥3 weeks later). An SRE was deﬁned as
radiation therapy or surgery to bone for prostate cancer,
pathological bone fracture, spinal cord compression, or change
of antineoplastic therapy to treat bone pain.2.4. Statistical analysis
In this post hoc analysis, baseline characteristics and treatment
effects were evaluated in the intent-to-treat population, deﬁned as
all randomly assigned patients, whereas safety data were
analyzed using descriptive statistics in all randomized patients
who received at least 1 dose of study drug. Baseline characteristics
and safety data were summarized descriptively for each treatment
group. Estimates of the medians and 95% conﬁdence intervals
(CIs) were determined using the Kaplan–Meier method. The HR
relative to placebo, with <1.00 favoring ENZA, was determined
using an unstratiﬁed Cox regression model with treatment as the
only covariate. The mean minimum concentration of ENZA and
the sum of ENZA plus N-desmethyl ENZA at weeks 5, 13, and
25 were adjusted for weight using log-linear regression and
summarized descriptively.
Kim et al. Medicine (2017) 96:27 Medicine3. Results
3.1. Patients
Of a total of 1717 patients, 148 East Asian patients were enrolled
at sites in Japan, Korea, and Singapore (ENZA, n=73; placebo,
n=75) (Fig. 1). Among East Asian patients, baseline demograph-
ic characteristics were well balanced between the ENZA and
placebo treatment arms, except that fewer ENZA-treated patients
had an ECOG Performance Status of 0 (68.5% vs. 80.0%) and
more had radical prostatectomy (16.4% vs. 6.7%) and soft-tissue
metastases (42.5% vs. 32.0%) (Table 1). Differences in baseline
disease characteristics were observed between East Asian patients
and the overall study population, including lower median body
weight, lower median body mass index, greater proportion of
patients with ECOG Performance Status of 0, and greater
proportion of patients with low baseline pain scores in East Asian
patients. Compared with the overall study population, East Asian
patients may have had a greater disease burden as indicated by a
greater proportion of patients with a Gleason score ≥8, bone
disease, baseline corticosteroid use, and prior antiandrogen
therapy. Notably, 40% of East Asian patients and 21% of
patients in the overall population received at least 2 prior
antiandrogen therapies. The median PSA and incidence of soft-
tissue disease at baseline were lower in East Asian patients than in
the overall study population.
Per the PREVAIL protocol, the interim analysis of centrally
assessed rPFS in the overall PREVAIL population was to occur
when 439 rPFS events had occurred; this event happened onMay
6, 2012. This cutoff date occurred during the enrollment period
in East Asia; therefore, rPFS was not evaluated by central review
for 51 East Asian patients (Fig. 1). For East Asian patients, results
for the investigator-assessed rPFS and OS are based on a data
cutoff of September 16, 2013, which corresponds to the
occurrence of 540 deaths in the overall study population as
speciﬁed by the protocol. At the September 16, 2013, data cutoff,
enrollment at all East Asian sites was complete and 55% of East
Asian patients in the ENZA arm and 20% of East Asian patients
in the placebo arm were still receiving study drug (Fig. 1). After
784 deaths in the overall study population (data cutoff, June 1,
2014), an updated exploratory analysis of OS was performed forTable 1
Baseline patient and disease characteristics.
East Asian pa
ENZA (n=73)
Median (range) age, y 72.0 (56–93)
Median (range) body weight, kg 65.5 (49–101)
Median (range) body mass index, kg/m2 24.0 (18–38)
Gleason score ≥8 at initial diagnosis, % 80.0
ECOG Performance Status=0, % 68.5
Pain score of 0–1 on BPI-SF Q3, % 83.6
Median PSA, ng/mL 24.2 (2–875)
Median LDH, IU/L 191.0 (136–903)
Baseline use of corticosteroids, % 6.8
Prior antiandrogen use, % 95.9
≥2 Prior antiandrogen therapies, % 37.0
≥4 Prior unique hormonal therapies, % 35.6
Prior radical prostatectomy, % 16.4
Bone disease, % 93.2
≥10 Bone metastases, % 35.6
Soft-tissue disease (lymph node, visceral, or other), % 42.5
BPI-SF Q3=Brief Pain Inventory Short Form question 3, ECOG=Eastern Cooperative Oncology Group, ENZ
4the overall PREVAIL population, and the results for East Asian
patients are presented here.3.2. Treatment effects
Relative to placebo, ENZA reduced the risk of centrally assessed
radiographic progression or death by 62% (HR, 0.38; 95% CI,
0.10–1.44) in East Asian patients and by 81% (HR, 0.19; 95%
CI, 0.15–0.23) in the overall population (Fig. 2A). Median rPFS
by central assessment was not reached among ENZA- or placebo-
treated East Asian patients. In East Asian patients, treatment
effects were consistent between centrally assessed and investiga-
tor-assessed radiographic progression (HR, 0.33; 95% CI,
0.19–0.56) (Fig. 2B). Median rPFS by investigator assessment
for East Asian patients was not reached in ENZA-treated
patients, compared with 8 months in placebo-treated patients.
Treatment with ENZA reduced the risk of death by 41% (HR,
0.59; 95% CI, 0.29–1.23) in East Asian patients and by 29%
(HR, 0.71; 95% CI, 0.60–0.84) in the overall study population
(Fig. 3A). In an updated OS analysis that included an additional
9 months of patient follow-up, ENZA reduced the risk of death
among East Asian patients by 37% (HR, 0.63; 95% CI,
0.36–1.10) relative to placebo (Fig. 3B).
Furthermore, treatment effects of ENZA versus placebo in East
Asian patients reﬂected in the secondary endpoint results,
including time to initiation of chemotherapy (HR, 0.33; 95%
CI, 0.19–0.60), median time to PSA progression (HR, 0.32; 95%
CI, 0.20–0.50), proportion of patients with a ≥50% decline
in PSA from baseline (68.5% vs. 14.7%, respectively), and
proportion of patients with objective soft-tissue response (60.0%
vs. 7.7%, respectively), were consistent with results in the overall
population (Table 2). In East Asian patients, median time to SRE
was not reached (95% CI, 20.1 to not reached) among ENZA-
or placebo-treated patients (HR, 1.35; 95% CI, 0.68–2.68)
(Table 2).3.3. Subsequent antineoplastic and endocrine therapies
In East Asian patients, 31.5% of those treated with ENZA and
68.0% of those receiving placebo used subsequent therapiestients (n=148) Overall ITT population (n=1717)
Placebo (n=75) ENZA (n=872) Placebo (n=845)
68.0 (42–89) 72.0 (43–93) 71.0 (42–93)
69.1 (42–88) 83.1 (49–162) 82.8 (34–160)
24.9 (18–30) 27.5 (18–47) 27.5 (15–51)
84.7 50.6 52.4
80.0 67.0 69.2
86.7 66.2 67.5
28.7 (0–1333) 54.1 (0–3182) 44.2 (0–3637)
193.0 (135–645) 185.0 (52–1816) 185.0 (67–2321)
8.0 4.0 4.3
97.3 87.2 86.4
42.7 21.4 20.0
37.3 18.8 17.4
6.7 25.9 26.6
89.3 85.0 81.7
32.0 32.7 32.2
32.0 59.3 59.6
A= enzalutamide, ITT= intent-to-treat, LDH= lactate dehydrogenase, PSA=prostate-speciﬁc antigen.
Median months (95% CI)
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Figure 2. (A) Kaplan–Meier estimates of centrally assessed rPFS for East Asian patients and the overall study population (data cutoff, May 6, 2012). (B)
Kaplan–Meier estimates of investigator-assessed rPFS for East Asian patients only (data cutoff, September 16, 2013). Dashed horizontal lines indicate median.
Hazard ratios are based on unstratiﬁed Cox regression models with treatment as the only covariate, with values <1.00 favoring ENZA. CI=conﬁdence interval,
ENZA=enzalutamide, HR=hazard ratio, ITT= intent-to-treat, NYR=not yet reached, rPFS= radiographic progression-free survival.
Kim et al. Medicine (2017) 96:27 www.md-journal.com(Table 3). The most common therapies received by East Asian
patients treated with ENZA were docetaxel (19.2%), estramus-
tine (8.2%), and ethinylestradiol (2.7%). The most common
therapies received by East Asian patients receiving placebo were
docetaxel (49.3%), estramustine (12.0%), and ethinylestradiol
(12.0%).3.4. Pharmacokinetics
The mean minimum plasma concentration of ENZA and the sum
of ENZA and N-desmethyl ENZA, its active metabolite, were
determined for East Asian and non-Asian patients (Table S1,
Supplemental Content, http://links.lww.com/MD/B759). When
adjusted for body weight, the concentration of ENZA plus its5active metabolite at weeks 5, 13, and 25 were similar in East
Asian patients and non-Asian patients, with geometric mean
ratios (East Asian vs. non-Asian) of 0.99, 1.01, and 1.03,
respectively.3.5. Safety
East Asian patients receiving ENZA had a more than 2-fold
longer duration of therapy than those receiving placebo (Table 4).
Among East Asian patients, the most frequent AEs (occurring in
≥10% of patients) were fatigue and decreased appetite, which
were mostly grade 2 (Table 5). Grade ≥3 AEs were reported in
31.5% of East Asian patients receiving ENZA and in 22.7% of
those receiving placebo. Treatment-related AEs grade ≥3 were
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Figure 3. (A) Kaplan–Meier estimates of OS for East Asian patients and overall study population (data cutoff, September 16, 2013). (B) Kaplan–Meier estimates of
updated OS for East Asian patients only (data cutoff, June 1, 2014). Dashed horizontal lines indicate median. Hazard ratios are based on unstratiﬁed Cox regression
models with treatment as the only covariate, with values <1.00 favoring ENZA. CI=conﬁdence interval, ENZA=enzalutamide, HR=hazard ratio, ITT= intent-to-
treat, NYR=not yet reached, OS=overall survival.
Kim et al. Medicine (2017) 96:27 Medicinereported in 1.4%ofEast Asian patients receiving ENZAand 2.7%
of those receiving placebo. No seizures were reported among East
Asian patients. Discontinuation of treatment because of anAEwas
reported by 3 (4.1%) ENZA- and 4 (5.3%) placebo-treated East
Asian patients. One (1.4%) ENZA- and 2 (2.7%) placebo-treated
East Asian patients required a dose reduction because of an AE.
The overall incidence of AEs and serious AEs was generally
consistent between East Asian patients and the overall population
(Table 4), with few differences observed.4. Discussion
In this post hoc analysis of PREVAIL, treatment effects and safety
in East Asian patients with asymptomatic or mildly symptomatic,6chemotherapy-naïve mCRPC were generally consistent with
those in the overall study population. Some of the observed
differences in baseline disease characteristics of East Asian
patients relative to the overall study populationmay be attributed
to differences in clinical practice in Japan, Korea, and Singapore
compared with Western countries. In Asian countries, patients
with prostate cancer are often diagnosed at more advanced stages
of disease, which may be related to less frequent PSA screening in
Asian countries than in Western countries.[1,9,10] In PREVAIL,
compared with the overall study population, a higher percentage
of East Asian patients had a Gleason score ≥8 and a greater
percentage had bone disease, suggesting a higher disease burden.
However, at baseline, East Asian patients had lower median PSA
levels and fewer had soft-tissue disease and pain. East Asian
Table 3
Subsequent antineoplastic and endocrine therapies.
East Asian patients (n=148) Overall ITT population (n=1717)
ENZA (n=73) Placebo (n=75) ENZA (n=872) Placebo (n=845)
Patients taking ≥1 subsequent therapy, n (%) 23 (31.5) 51 (68.0) 382 (43.8) 642 (76.0)
Antineoplastic agents 18 (24.7) 41 (54.7) 308 (35.3) 515 (60.9)
Cabazitaxel 2 (2.7) 4 (5.3) 51 (5.8) 110 (13.0)
Carboplatin 1 (1.4) 0 7 (0.8) 11 (1.3)
Cyclophosphamide 0 3 (4.0) 7 (0.8) 12 (1.4)
Docetaxel 14 (19.2) 37 (49.3) 286 (32.8) 479 (56.7)
Estramustine 6 (8.2) 9 (12.0) 8 (0.9) 11 (1.3)
Mitoxantrone 0 2 (2.7) 5 (0.6) 9 (1.1)
Uftoral 0 1 (1.3) 0 1 (0.1)
Endocrine therapy 7 (9.6) 22 (29.3) 200 (22.9) 438 (51.8)
Abiraterone acetate 3 (4.1) 6 (8.0) 179 (20.5) 385 (45.6)
Bicalutamide 1 (1.4) 7 (9.3) 16 (1.8) 41 (4.9)
Diethylstilbestrol 1 (1.4) 0 11 (1.3) 8 (0.9)
Ethinylestradiol 2 (2.7) 9 (12.0) 2 (0.2) 9 (1.1)
Flutamide 1 (1.4) 4 (5.3) 3 (0.3) 7 (0.8)
ENZA= enzalutamide, ITT= intent-to-treat.
Table 2
Secondary endpoints.
East Asian patients (n=148) Overall ITT population (n=1717)
ENZA (n=73) Placebo (n=75) ENZA (n=872) Placebo (n=845)
Median (95% CI) time to initiation of chemotherapy, mo NYR (NYR–NYR) 12.2 (8.4–NYR) 28.0 (25.8–NYR) 10.8 (9.7–12.2)
HR (95% CI) 0.33 (0.19–0.60) 0.35 (0.30–0.40)
Median (95% CI) time to PSA progression, mo 11.1 (6.7–11.3) 3.7 (2.8–4.6) 11.2 (11.1–13.7) 2.8 (2.8–2.9)
HR (95% CI) 0.32 (0.20–0.50) 0.17 (0.15–0.20)
Median (95% CI) time to SRE, mo NYR (20.1–NYR) NYR (20.1–NYR) 31.1 (29.5–NYR) 31.3 (23.9–NYR)
HR (95% CI) 1.35 (0.68–2.68) 0.72 (0.61–0.84)
PSA response ≥50% decline from baseline, % (95% CI) 68.5 (56.6–78.9) 14.7 (7.6–24.7) 78.0 (75.1–80.7) 3.5 (2.3–5.0)
Best objective soft-tissue response, %
∗
60.0 7.7 58.8 5.0
CI= conﬁdence interval, ENZA= enzalutamide, HR=hazard ratio, ITT= intent-to-treat, NYR=not yet reached, PSA=prostate-speciﬁc antigen, SRE= skeletal-related event.
∗
Includes complete and partial response, assessed by investigator in patients with measurable disease: East Asian patients, ENZA (n=20), placebo (n=13); overall ITT population, ENZA (n=396), placebo (n=381).
Kim et al. Medicine (2017) 96:27 www.md-journal.compatients had an increased use of corticosteroids, commonly used
to treat pain associated with bone disease, which may account for
the larger proportion of patients with low baseline pain
compared with the overall population. The percentage of East
Asian patients who had received at least 2 antiandrogen therapies
prior to treatment with ENZA was higher than in the overall
study population. Notably, hormone therapy is widely used for
treatment of early stage prostate cancer in Japan,[10] whereas
radical prostatectomy is the preferred treatment in Korea.[3]
Some baseline disease characteristics may also be attributed to
differences in ethnicity. It has previously been shown that, inTable 4
Overall AE summary.
East Asian patients (n=
ENZA (n=73) Pla
Median duration of treatment, mo 14.0
AEs, n (%) 69 (94.5)
Serious AEs, n (%) 23 (31.5)
Grade ≥3 AEs, n (%) 23 (31.5)
Treatment-related grade ≥3 AEs, n (%) 1 (1.4)
Results are from the September 16, 2012, data cutoff.
AE= adverse event, ENZA= enzalutamide.
7general, Asian men have a lower baseline PSA than Caucasian
men.[25–29] Studies of PSA screening in Korea,[29] Japan,[30] and
Singapore[25] have identiﬁed increased percentages of patients
with prostate cancer in groups with PSA levels below the
commonly accepted 4.0 ng/mL threshold. Some groups have
suggested that a lower PSA cutoff value should be used to
recommend prostate biopsy for Asian patients.[27,29,31] In
PREVAIL, ENZA-treated East Asian patients had a lower PSA
response rate (68.5%) than those in the overall study population
(78.0%). Similar results were obtained in other studies of Asian
men with mCRPC, including phase II studies of abiraterone148) Overall safety population (n=1715)
cebo (n=75) ENZA (n=871) Placebo (n=844)
6.1 16.6 4.6
62 (82.7) 844 (96.9) 787 (93.2)
10 (13.3) 279 (32.0) 226 (26.8)
17 (22.7) 374 (42.9) 313 (37.1)
2 (2.7) 67 (7.7) 54 (6.4)
[4] Haas GP, Delongchamps N, Brawley OW, et al. The worldwide
Table 5
Most common AEs: Comparison with overall population.
East Asian patients (n=139), n (%) Overall safety population (n=1715), n (%)
ENZA (n=73) Placebo (n=75) ENZA (n=871) Placebo (n=844)
Most common AEs
∗
Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Fatigue 15 (20.5) 1 (1.4) 5 (6.7) 0 310 (35.6) 16 (1.8) 218 (25.8) 16 (1.9)
Decreased appetite 15 (20.5) 0 13 (17.3) 1 (1.3) 158 (18.1) 2 (<1) 136 (16.1) 6 (<1)
Constipation 13 (17.8) 0 6 (8.0) 0 193 (22.2) 4 (<1) 145 (17.2) 3 (<1)
Upper respiratory tract infection 11 (15.1) 0 5 (6.7) 0 53 (6.1) 0 30 (3.6) 0
Fall 11 (15.1) 0 2 (2.7) 0 101 (11.6) 12 (1.4) 45 (5.3) 6 (<1)
Back pain 10 (13.7) 2 (2.7) 7 (9.3) 0 235 (27.0) 22 (2.5) 187 (22.2) 25 (3.0)
Pollakiuria 9 (12.3) 0 4 (5.3) 0 50 (5.7) 1 (<1) 37 (4.4) 0
Nausea 8 (11.0) 0 7 (9.3) 0 201 (23.1) 9 (1.0) 190 (22.5) 4 (<1)
Results are from the September 16, 2012, data cutoff.
AE= adverse event, ENZA= enzalutamide.
∗
Occurring in ≥10% of East Asian patients in the ENZA-treated group at a higher incidence than in the placebo group.
Kim et al. Medicine (2017) 96:27 Medicineacetate and prednisolone, in which 43% to 60%of Asian patients
had a PSA response.[32,33] Similarly, in studies of cabazitaxel in
Japanese[34] and Korean,[35] patients with mCRPC previously
treated with chemotherapy, PSA responses were achieved by
29% and 32% of patients, respectively.
AEs commonly reported by East Asian patients treated with
ENZA in PREVAIL were similar to those reported by the overall
study population. AEs that were more common among East
Asian patients than in the overall study population included
upper respiratory tract infection, pollakiuria, fall, and decreased
appetite. Among ENZA-treated East Asian patients, common
AEs (fatigue and back pain) reported at a grade level≥3 were rare
(occurring in <3% of patients).
The results from East Asian patients in PREVAIL should be
interpreted with caution given the small number of Japanese,
Korean, and Singaporean patients enrolled in the study. The
heterogeneity of ethnicities across East Asia also precludes
generalizing these results for the rest of Asia. In addition,
PREVAIL was not designed to investigate the impact of any
differences observed in baseline demographic or disease
characteristics between East Asian patients and the overall
population, nor was it powered to detect treatment effects or
safety differences between ENZA and placebo in East Asian
patients. These limitations impact median estimates of OS and
rPFS in East Asian patients as well as the ability to detect
differences in AEs between East Asian patients receiving ENZA
or placebo. However, our analysis showed that results in East
Asian patients were consistent with those in the overall
population, which was sufﬁciently powered to detect treatment
effects and the safety of ENZA compared with placebo.
In summary, this analysis showed that results in chemothera-
py-naïve East Asian men with asymptomatic or minimally
symptomatic mCRPC were consistent with those observed in the
overall PREVAIL study population.
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